PDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of “Buy” by Brokerages

Shares of PDS Biotechnology Co. (NASDAQ:PDSB) have been assigned a consensus recommendation of “Buy” from the five research firms that are currently covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $14.25.

Several equities analysts have commented on PDSB shares. Alliance Global Partners raised shares of PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. StockNews.com raised shares of PDS Biotechnology from a “sell” rating to a “hold” rating in a research report on Friday. Finally, HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of PDS Biotechnology in a research report on Thursday, October 24th.

PDS Biotechnology Trading Up 0.3 %

PDS Biotechnology stock opened at $3.20 on Friday. The company’s fifty day simple moving average is $3.24 and its 200-day simple moving average is $3.27. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.45. PDS Biotechnology has a 12 month low of $2.53 and a 12 month high of $6.85. The stock has a market cap of $117.82 million, a P/E ratio of -2.62 and a beta of 1.93.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.08. During the same quarter in the previous year, the firm earned ($0.37) EPS. As a group, sell-side analysts forecast that PDS Biotechnology will post -1.24 EPS for the current fiscal year.

Institutional Investors Weigh In On PDS Biotechnology

Several hedge funds have recently made changes to their positions in PDSB. Inspirion Wealth Advisors LLC lifted its stake in PDS Biotechnology by 1.4% during the second quarter. Inspirion Wealth Advisors LLC now owns 359,894 shares of the company’s stock worth $1,054,000 after purchasing an additional 4,917 shares during the period. Tempus Wealth Planning LLC bought a new position in PDS Biotechnology during the second quarter worth about $55,000. Ground Swell Capital LLC bought a new position in PDS Biotechnology during the second quarter worth about $67,000. Vontobel Holding Ltd. increased its holdings in shares of PDS Biotechnology by 233.3% during the third quarter. Vontobel Holding Ltd. now owns 40,000 shares of the company’s stock worth $153,000 after buying an additional 28,000 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of PDS Biotechnology during the second quarter worth approximately $115,000. Institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.